Page last updated: 2024-08-05 14:58:42
dopamine agonist
A drug that binds to and activates dopamine receptors.
ChEBI ID: 51065
Members (26)
| Member | Definition | Class |
|---|---|---|
| 7-hydroxy-2-(n-n-propyl-n-(3-iodo-2'-propenyl)-amino)tetralin | A tertiary amino compound that consists of 2-amino-7-hydroxytetralin in which the two amino hydrogens are substituted by 2E)-3-iodoallyl and propyl groups. This ligand has uniquely high affinity and selectivity for the D3 receptor. | 2-{[(2E)-3-iodoprop-2-en-1-yl](propyl)amino}tetralin-7-ol |
| a 77636 | An isochromene that is 3,4-dihydroisochromene-5,6-diol bearing additional aminomethyl and 1-adamantyl substituents at positions 1 and 3 respectively (the 1R,3S-diastereomer). Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo. | (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol |
| a 77636 | A hydrochloride salt obtained by mixing equimolar amounts of (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol with hydrochloric acid. Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo. | (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride |
| amantadine hydrochloride | A hydrochloride obtained by combining amantadine and hydrochloric acid in equimolar amounts. | amantadine hydrochloride |
| apomorphine | apomorphine | |
| bromocriptine | bromocriptine | |
| cabergoline | An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. | cabergoline |
| carmoxirole | An indolecarboxylic acid that is indole-5-carboxylic acid bearing an additional 4-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)butyl substituent at position 3. Selective, peripherally acting dopamine D2 receptor agonist. Modulates noradrenalin release and sympathetic activation. Displays antihypertensive properties in vivo. | carmoxirole |
| dihydroergotamine | Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension. | dihydroergotamine |
| fenoldopam | fenoldopam | |
| lisuride | lisuride | |
| ly 404039 | An organic heterobicyclic compound that is (1S,5R)-2-thiabicyclo[3.1.0]hexane carrying oxo, oxo, amino, carboxy, and carboxy groups at positions 2, 2, 4S, 4S, and 6S, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 mGluR3 (Ki = 149 nM and 92 nM, respectively) and exhibits antipsychotic and anxiolytic efficacy in animal models. | LY404039 |
| lysergic acid diethylamide | An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. | lysergic acid diethylamide |
| mesulergine | A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors. | mesulergine |
| metergoline | An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. | metergoline |
| mk 458 | The hydrochloride salt of naxagolide. | naxagolide hydrochloride |
| N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide | A hydrobromide salt prepared from N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine. | N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide |
| naxagolide | An organic heterotricyclic compound that is (4aR,10bR)-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazine substituted by propyl and hydroxy groups at positions 4 and 9, respectively. It is a potent dopamine D2-receptor agonist and its hydrochloride salt was under clinical development by Merck & Co as a potential antiparkinsonian agent (now discontinued). | naxagolide |
| pergolide | A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | pergolide |
| pergolide mesylate | A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | pergolide mesylate |
| pramipexole | A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. | pramipexole |
| quinpirole | A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist. | quinpirole |
| ropinirole | ropinirole | |
| sk&f 77434 | A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, an allyl substituent at position 3 and two hydroxy substituents at positions 7 and 8. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo. | N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol |
| sk&f 77434 | A hydrobromide salt prepared from N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo. | N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide |
| sk&f 83959 | A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a 3-methylphenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 6 and two hydroxy substituents at positions 7 and 8. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine. | N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol |
Research
Studies (27,777)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 14,069 (50.65) | 18.7374 |
| 1990's | 5,587 (20.11) | 18.2507 |
| 2000's | 4,181 (15.05) | 29.6817 |
| 2010's | 3,053 (10.99) | 24.3611 |
| 2020's | 887 (3.19) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 2,326 (7.27%) | 5.53% |
| Reviews | 2,266 (7.09%) | 6.00% |
| Case Studies | 2,293 (7.17%) | 4.05% |
| Observational | 37 (0.12%) | 0.25% |
| Other | 25,057 (78.35%) | 84.16% |
Protein Targets (297)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.7312 | 1 | 2 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 9.4562 | 2 | 2 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 29.6578 | 4 | 21 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.1974 | 1 | 6 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 31.6228 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 25.5107 | 7 | 21 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 16.3738 | 2 | 8 |
| arylsulfatase A | Homo sapiens (human) | Potency | 21.2554 | 1 | 4 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 25.5112 | 2 | 6 |
| Ataxin-2 | Homo sapiens (human) | Potency | 21.3452 | 2 | 10 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 11.2767 | 2 | 7 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 13.8198 | 2 | 6 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 16.3601 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 9.1038 | 2 | 8 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 47.3936 | 1 | 2 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 24.2539 | 1 | 4 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 19.9722 | 2 | 7 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 26.0818 | 1 | 9 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 33.5520 | 2 | 2 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 10.0413 | 2 | 4 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 30.2586 | 1 | 2 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 12.5694 | 2 | 2 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 17.5994 | 1 | 3 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 24.9404 | 1 | 3 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 33.7235 | 1 | 9 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 12.5694 | 2 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 50.7058 | 2 | 12 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 16.9385 | 1 | 4 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 35.7168 | 1 | 2 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 43.1137 | 1 | 2 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 7.4020 | 1 | 10 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 15.7915 | 1 | 3 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 13.6804 | 2 | 12 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 12.5384 | 2 | 10 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 32.2774 | 1 | 3 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 0.9925 | 3 | 18 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 23.2809 | 1 | 1 |
| D(3) dopamine receptor isoform e | Homo sapiens (human) | Potency | 22.3747 | 1 | 3 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 29.8554 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 26.6795 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 39.9850 | 1 | 2 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 1.0735 | 1 | 8 |
| endonuclease IV | Escherichia coli | Potency | 25.2855 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 16.9049 | 9 | 27 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 23.7101 | 1 | 2 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 36.8402 | 10 | 23 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 20.1269 | 1 | 21 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 19.9581 | 4 | 4 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 21.9987 | 2 | 3 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 25.0086 | 2 | 5 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 33.2679 | 1 | 4 |
| G | Vesicular stomatitis virus | Potency | 43.1137 | 1 | 2 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 13.6803 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 13.6804 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 13.6803 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 13.6803 | 1 | 6 |
| geminin | Homo sapiens (human) | Potency | 17.0201 | 4 | 18 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 26.7475 | 2 | 8 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 22.0164 | 1 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 16.5871 | 2 | 15 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 28.7968 | 1 | 2 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 9.0179 | 2 | 8 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 20.8662 | 1 | 2 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 31.3736 | 1 | 2 |
| guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 26.1216 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 22.2501 | 2 | 12 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 68.9163 | 2 | 6 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 43.1137 | 1 | 2 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 22.3872 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 26.8325 | 1 | 1 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 3.9811 | 2 | 2 |
| IDH1 | Homo sapiens (human) | Potency | 7.3322 | 1 | 3 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 71.4151 | 2 | 5 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 43.1137 | 1 | 4 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 23.1103 | 1 | 3 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 23.1103 | 1 | 3 |
| Interferon beta | Homo sapiens (human) | Potency | 43.1137 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 16.5577 | 2 | 10 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 25.1189 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 11.4239 | 1 | 1 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 40.8227 | 3 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 48.3892 | 1 | 4 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 20.6706 | 2 | 14 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 27.2854 | 1 | 4 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 13.9897 | 2 | 5 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 29.8496 | 3 | 6 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 6.3096 | 2 | 2 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 7.9433 | 1 | 1 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 58.0479 | 1 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 30.6493 | 2 | 6 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.1065 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.2197 | 2 | 7 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 18.2436 | 3 | 10 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 29.5888 | 2 | 5 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 19.5904 | 1 | 4 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 39.4186 | 1 | 5 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 14.7389 | 3 | 4 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 14.9803 | 2 | 3 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.7623 | 1 | 7 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 5.9665 | 1 | 2 |
| polyprotein | Zika virus | Potency | 33.2679 | 1 | 4 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 8.7834 | 1 | 3 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 13.3248 | 1 | 9 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.5258 | 2 | 7 |
| progesterone receptor | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 12.5893 | 2 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 21.2505 | 2 | 4 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 101.9290 | 1 | 2 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 7.5740 | 1 | 9 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 26.2911 | 3 | 6 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 45.7999 | 2 | 4 |
| RGS12 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 20.2904 | 4 | 9 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 8.3446 | 1 | 2 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 8.3446 | 1 | 2 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 71.4151 | 2 | 5 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 10.9740 | 1 | 2 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.7750 | 1 | 3 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.2632 | 2 | 34 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 29.0310 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 14.7909 | 4 | 16 |
| Thrombopoietin | Homo sapiens (human) | Potency | 10.0000 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.3767 | 2 | 14 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0089 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 40.7811 | 4 | 9 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 12.9623 | 2 | 3 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 5.9665 | 1 | 2 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 5.9665 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 63.5144 | 1 | 2 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 20.1340 | 2 | 3 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 72.5478 | 1 | 3 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 30.6794 | 1 | 4 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 20.8662 | 1 | 2 |
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.0041 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 2.5516 | 3 | 8 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.6848 | 12 | 15 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.1718 | 5 | 9 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 2.5516 | 3 | 8 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 3.5080 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 1.6179 | 4 | 9 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 5.0020 | 2 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.7600 | 2 | 2 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | Ki | 5.0465 | 2 | 2 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.7600 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.0123 | 1 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 2.0961 | 8 | 12 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.1390 | 9 | 11 |
| 5-hydroxytryptamine receptor 2A | Sus scrofa (pig) | Ki | 0.0490 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.0170 | 2 | 6 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.0120 | 4 | 8 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.2516 | 4 | 6 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.1706 | 2 | 6 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0544 | 5 | 10 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.0815 | 17 | 19 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 5.0968 | 3 | 4 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 5.0968 | 3 | 4 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.2043 | 1 | 5 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.1069 | 1 | 5 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 5.4338 | 3 | 4 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 3.3397 | 3 | 3 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.0208 | 1 | 5 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 1.0603 | 6 | 11 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 20.8000 | 1 | 2 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 0.2050 | 2 | 2 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.1754 | 6 | 7 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.2612 | 7 | 8 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 1.3440 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 3.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 0.3660 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 0.3630 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.3498 | 1 | 5 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.1720 | 1 | 5 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.0677 | 1 | 5 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.0338 | 2 | 6 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0239 | 1 | 5 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.0204 | 2 | 6 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.4267 | 1 | 5 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0604 | 2 | 6 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-synuclein | Homo sapiens (human) | IC50 | 16.3000 | 1 | 2 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 | 2.2810 | 1 | 1 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 1.5210 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 281.6775 | 2 | 4 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | Ki | 503.4675 | 2 | 4 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 1.4795 | 1 | 2 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.6163 | 2 | 3 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0410 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 42.1538 | 4 | 5 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 236.0625 | 3 | 8 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| Catechol O-methyltransferase | Rattus norvegicus (Norway rat) | Ki | 0.0025 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 0.1387 | 1 | 3 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 3.2496 | 2 | 4 |
| D | Bos taurus (cattle) | IC50 | 0.2724 | 12 | 17 |
| D | Rattus norvegicus (Norway rat) | IC50 | 1.5593 | 15 | 23 |
| D | Bos taurus (cattle) | Ki | 13.3346 | 2 | 3 |
| D | Mus musculus (house mouse) | Ki | 0.1405 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | Ki | 8.5958 | 11 | 12 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 1.0392 | 2 | 6 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 38.1967 | 20 | 31 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Ki | 0.0370 | 2 | 2 |
| D(1B) dopamine receptor | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 3.4517 | 3 | 3 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 1.0196 | 13 | 21 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 1.2771 | 4 | 8 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1541 | 19 | 27 |
| D(2) dopamine receptor | Bos taurus (cattle) | Ki | 0.8555 | 5 | 6 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.8188 | 75 | 99 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.3740 | 19 | 21 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.0074 | 2 | 6 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.0352 | 44 | 60 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0098 | 6 | 7 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.0308 | 18 | 24 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | IC50 | 10.1367 | 3 | 3 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0071 | 2 | 4 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0071 | 1 | 2 |
| Genome polyprotein | Zika virus | IC50 | 17.3200 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 | 216.7000 | 2 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 2.1465 | 1 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.6797 | 2 | 3 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.0075 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 4.6170 | 3 | 4 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.0014 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Lysine-specific demethylase 4E | Homo sapiens (human) | Ki | 1.9200 | 1 | 1 |
| Metabotropic glutamate receptor 2 | Homo sapiens (human) | Ki | 0.1490 | 1 | 1 |
| Metabotropic glutamate receptor 3 | Homo sapiens (human) | Ki | 0.0920 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 2.8000 | 1 | 1 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 12.6000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 0.1202 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 107.3600 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 107.3600 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 5.1925 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 4.4460 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 1 |
| Sodium-dependent dopamine transporter | Macaca fascicularis (crab-eating macaque) | Ki | 0.3400 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0150 | 3 | 4 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 0.0630 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.1950 | 2 | 2 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.3660 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.3630 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.5900 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.3130 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 20.8000 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 49.9000 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | IC50 | 4.0710 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | Ki | 1.3570 | 1 | 1 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2200 | 1 | 1 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
Activation Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | EC50 | 0.0092 | 2 | 2 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Kd | 0.0802 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | EC50 | 0.1515 | 5 | 9 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | EC50 | 16.1138 | 2 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | EC50 | 0.0098 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Sus scrofa (pig) | EC50 | 0.0034 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | EC50 | 0.0130 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | EC50 | 0.6094 | 1 | 3 |
| Adenosine receptor A2a | Homo sapiens (human) | EC50 | 0.0490 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | EC50 | 0.0326 | 2 | 2 |
| D(1) dopamine receptor | Carassius auratus (goldfish) | EC50 | 0.0082 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | EC50 | 1.9591 | 8 | 16 |
| D(1A) dopamine receptor | Homo sapiens (human) | Kd | 0.3540 | 1 | 2 |
| D(1B) dopamine receptor | Homo sapiens (human) | EC50 | 0.1000 | 1 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | EC50 | 0.2692 | 71 | 99 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0147 | 12 | 14 |
| D(2) dopamine receptor | Homo sapiens (human) | Kd | 0.0080 | 3 | 3 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Kd | 1.3499 | 4 | 30 |
| D(3) dopamine receptor | Homo sapiens (human) | EC50 | 0.0140 | 34 | 43 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0324 | 3 | 5 |
| D(3) dopamine receptor | Homo sapiens (human) | Kd | 0.0000 | 1 | 1 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Kd | 0.0001 | 1 | 1 |
| D(4) dopamine receptor | Homo sapiens (human) | EC50 | 0.0285 | 20 | 22 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0042 | 3 | 3 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | EC50 | 0.0230 | 1 | 2 |
| Dipeptidyl peptidase 4 | Mus musculus (house mouse) | EC50 | 0.0034 | 1 | 1 |
| Genome polyprotein | Zika virus | EC50 | 13.0200 | 2 | 2 |
| heat shock protein 90 | Candida albicans | EC50 | 3.3640 | 1 | 1 |
| Heparanase | Homo sapiens (human) | Kd | 1,000.0000 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | Kd | 0.0045 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | EC50 | 0.1660 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Kd | 0.0122 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Kd | 0.0160 | 1 | 1 |
| Metabotropic glutamate receptor 2 | Homo sapiens (human) | EC50 | 0.0234 | 1 | 1 |
| Metabotropic glutamate receptor 3 | Homo sapiens (human) | EC50 | 0.0480 | 1 | 1 |
| Metabotropic glutamate receptor 5 | Homo sapiens (human) | EC50 | 0.0019 | 1 | 1 |
| Metabotropic glutamate receptor 8 | Homo sapiens (human) | EC50 | 47.7730 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | EC50 | 0.0510 | 1 | 1 |
| mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 | 92.4557 | 2 | 6 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | EC50 | 0.0017 | 1 | 4 |
Other Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Activity | 0.0100 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Activity | 0.0280 | 1 | 1 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Activity | 0.0009 | 1 | 1 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | Activity | 1.6590 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Activity | 0.0071 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Activity | 0.0026 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Activity | 0.0095 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Activity | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | Activity | 1.2740 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Activity | 0.5620 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Activity | 0.0910 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Activity | 0.0180 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Kb | 0.0110 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Kbapp | 0.0160 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Activity | 0.0300 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Activity | 0.1230 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Activity | 0.0910 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Activity | 0.0310 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Activity | 0.0410 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Activity | 0.0300 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | K 0.5 | 5.0000 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | KL | 0.0210 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Activity | 0.0090 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | ID50 | 0.0390 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | KL | 0.2060 | 1 | 1 |
| D(1B) dopamine receptor | Homo sapiens (human) | ID50 | 0.0390 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | Activity | 0.0740 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | ID50 | 0.0390 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Intrinsic activity | 0.0950 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | K 0.5 | 1.1394 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | KL | 0.1665 | 2 | 2 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | KL | 1.0000 | 1 | 1 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Activity | 5.0070 | 2 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | ED50 | 0.0037 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | ID50 | 0.0390 | 1 | 1 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | K 0.5 | 0.0045 | 1 | 1 |
| D(4) dopamine receptor | Homo sapiens (human) | Activity | 0.0049 | 1 | 1 |
| D(4) dopamine receptor | Homo sapiens (human) | ID50 | 0.0390 | 1 | 1 |
| D(4) dopamine receptor | Homo sapiens (human) | Intrinsic activity | 0.1000 | 1 | 1 |
| Delta-type opioid receptor | Homo sapiens (human) | Activity | 0.0189 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | Activity | 0.0982 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Activity | 0.1040 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Activity | 0.0127 | 1 | 1 |
| interferon gamma precursor | Homo sapiens (human) | AC50 | 39.0000 | 1 | 1 |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | Activity | 0.0632 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Activity | 0.0012 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Activity | 0.0177 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Activity | 0.0038 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Activity | 0.0369 | 1 | 1 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Activity | 0.0217 | 1 | 1 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Activity | 0.0152 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Activity | 1.1320 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Activity | 0.0897 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Km | 30.0000 | 2 | 2 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | Km | 17.0000 | 2 | 2 |